Stephen Jones, MD
Family Medicine · Shelby, NCNPI 1730130881
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,701 of the $2,277 with a category attached, or 74.7%. 21 manufacturers reported payments, led by Novartis at 41.7% of the total. Reporting peaked in 2019 at $1,224 and has fallen 98.8% since, to $15 in 2024.
Across 89 payments — averaging $25.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$949
- Novo Nordisk$230
- Takeda Pharmaceuticals U.S.A., Inc.$201
- Lilly USA, LLC$136
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$112
- AbbVie$104
- plus $545 from 15 others
Across 451 payments — averaging $10,136 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$956K
- Genentech, Inc.$619K
- Novartis$478K
- Sanofi US Services Inc.$415K
- Pfizer$300K
- Amgen$296K
- plus $1.5M from 11 others
What the payments were for
- Travel & lodging$57625%
- Food & beverage$1,70175%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QBW251$570
How this compares
$2,277 in reported general payments places this provider in the 80th percentile of 3,444 family medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $11,176 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 35 | $11,142 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 26 | $5,762 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 26 | $978 |
| Levothyroxine Sodium | 28 | $394 |
| Gabapentin | 24 | $371 |
| Omeprazole | 27 | $257 |
| Diclofenac Sodium | 19 | $244 |
| Atorvastatin Calcium | 26 | $237 |
| Rosuvastatin Calcium | 15 | $133 |
| Fluconazole | 11 | $121 |
| Metformin Hcl | 16 | $105 |
| Losartan Potassium | 17 | $101 |
| Amlodipine Besylate | 19 | $84 |
| Prednisone | 11 | $79 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Shelby
- William CromwellRaleigh$879K
- Steve VacalisGastonia$693K
- David DundeeWinston Salem$633K
- Kevin SodenCharlotte$558K
- Brian ForrestApex$398K
- Joseph KonenCharlotte$322K
- Richard RachimaCharlotte$294K
- Dimitrios HondrosCharlotte$275K
- Domingo Rodriguez-CueGarner$253K
- Christopher ChaoCary$201K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.